News About: Pharm. Industry
BMS Korea renews commitment to anti-hepatitis campaign on World Hepatitis Day
Marking World Hepatitis Day, the head of BMS Korea said the company will become a forerunner to stop the spread of hepatitis through its campaign calling for a stronger prevention and fair access to treatment.
“Eve...
Daewoong launching Ursa’s new campaign
Daewoong Pharmaceutical said Monday it has launched a new advertising campaign promoting the efficacy of Ursa, the best-selling hepatic function medicine here.
The new advertising campaign for Ursa is designed to c...
Korean drug makers still stuck in quagmire
Korean pharmaceutical companies are feeling pains from all sides. Relying too much on selling cheap generic drugs instead of developing original drugs, they lack competitiveness to take on global players.
On its p...
Chong Kun Dang seeks overseas expansion
Chong Kun Dang Pharmaceutical is aiming to go global with rosuvastain, a member of the drug class of statins.
The company on Thursday said in its regulatory filing that its rosuvastatin patent has received the gree...
Hanbul Pharm goes bankrupt
Hanbul Pharmaceutical, the country’s mid-sized drug maker in terms of sales, was declared bankrupt Wednesday after failing to honor commercial papers, sending out shocking signals to local wholesalers.
The company,...
KPMA seeking to change ”generic” to other name
The Korea Pharmaceutical Manufacturers Association (KPMA) is considering changing “generic drug” to other appropriate name in an effort to dispel general public’s negative image
In a board of directors meeting on ...
Government seeking to boost drug exports in Latin America
The government is revving up its efforts to help Korean drug makers solidify their footholds in Latin American countries as the region has emerged as a key destination of Korea’s homegrown drugs, according to the Mini...
Boryung grants Stendhal exclusive rights to Kanarb, novel antihypertensive agent
Boryung Pharmaceutical has granted Latin American specialty company Stendhal exclusive commercialization rights for Mexico, Venezuela, Colombia, Perú, Ecuador and most of Central American countries, to its novel antih...
Wild M&A rumors spread
Korean pharmaceutical companies are considering mergers and acquisitions (M&As) in order to make them more productive and profitable, but groundless information on M&A may give adverse effect to firms, critics say.
...
Hanmi to distribute Wakamoto’s MaQuid to treat diabetic macular edema
Hanmi Pharmaceutical said Tuesday that it has signed a distribution agreement with a Japanese company Wakamoto for the exclusive sale of Wakamoto’ MaQaid for the treatment of diabetic macular edema (DME), a sight-thre...
